ImmunoGen Inc. (IMGN)
NASDAQ: IMGN
· Real-Time Price · USD
31.23
0.00 (0.00%)
At close: Feb 09, 2024, 9:58 PM
ImmunoGen Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | 113.42M | 83.15M | 49.87M | 41.17M | 15.38M | 14.16M | 38.08M | 27.99M | 9.21M | 16.95M | 15.71M |
Cost of Revenue | 2.15M | 909K | 626K | 176K | 424K | n/a | n/a | 34.41M | n/a | n/a | 34.41M |
Gross Profit | 111.27M | 82.24M | 49.24M | 40.99M | 14.95M | 14.16M | 38.08M | -6.42M | 9.21M | 16.95M | -18.71M |
Operating Income | 25.96M | -4.19M | -42.39M | -59.56M | -77.43M | -61.05M | -22.85M | -34.55M | -34.23M | -27.37M | -28.92M |
Interest Income | 4.84M | 1.91M | 2.17M | 2.16M | 1.54M | 590K | n/a | n/a | n/a | n/a | n/a |
Pretax Income | 29.58M | -3.37M | -41.01M | -57.79M | -77.75M | -62.02M | -24.14M | -37.17M | -37.34M | -30.74M | -34.05M |
Net Income | 30.75M | -4.25M | -40.57M | -59.01M | -78.08M | -62.99M | -25.44M | -37.17M | -37.34M | -30.74M | -34.05M |
Selling & General & Admin | 37.74M | 36.36M | 40.02M | 42.06M | 33.62M | 23.79M | 16.65M | 13.58M | 10.3M | 9.73M | 10.21M |
Research & Development | 47.57M | 50.08M | 51.62M | 58.48M | 59.18M | 51.42M | 44.28M | 48.97M | 33.15M | 34.59M | 34.41M |
Other Expenses | -164K | -8K | n/a | n/a | n/a | 110K | -98K | -467K | -354K | 208K | -467K |
Operating Expenses | 85.31M | 86.43M | 91.64M | 100.55M | 92.8M | 75.22M | 60.93M | 62.55M | 43.44M | 44.32M | 44.62M |
Interest Expense | 1.05M | 1.08M | 853K | 971K | 867K | 1.08M | 1.25M | 2.15M | 2.75M | 3.58M | 4.67M |
Selling & Marketing Expenses | n/a | n/a | n/a | 18.27M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 87.47M | 87.34M | 92.26M | 100.73M | 92.8M | 75.22M | 60.93M | 62.55M | 43.44M | 44.32M | 44.62M |
Income Tax Expense | -1.17M | 877K | -448K | 1.22M | 326K | 968K | 1.29M | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 273.34M | 263.45M | 258.85M | 253.26M | 250.82M | 253.34M | 253.26M | 210.86M | 204.84M | 199.89M | 198.84M |
Shares Outstanding (Diluted) | 287.59M | 263.45M | 258.85M | 254.41M | 253.51M | 253.34M | 253.26M | 215.83M | 204.84M | 199.89M | 198.84M |
EPS (Basic) | 0.10 | -0.02 | -0.16 | -0.23 | -0.31 | -0.25 | -0.1 | -0.17 | -0.18 | -0.15 | -0.17 |
EPS (Diluted) | 0.10 | -0.02 | -0.16 | -0.23 | -0.31 | -0.25 | -0.1 | -0.17 | -0.18 | -0.15 | -0.17 |
EBITDA | 30.64M | -2.29M | -40.16M | -56.82M | -78M | -60.94M | -22.48M | -35.02M | -34.59M | -27.16M | -29.38M |
EBIT | 30.64M | -2.29M | -40.16M | -56.82M | -76.89M | -60.94M | -22.9M | -35.02M | -34.59M | -27.16M | -29.38M |
Depreciation & Amortization | 423K | 427K | 2.23M | 2.74M | -574K | 110K | 375K | 462K | 462K | 542K | 551K |